SCHEMBL13623006

SCHEMBL13623006

CC(C)(C)OC(=O)Nc1cccc(CNC(=O)c2cccc(Nc3nc(Cl)ncc3Cl)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.47
BRD4 O60885 4/20 0.46
STK17B O94768 1/20 0.46
STK17A Q9UEE5 1/20 0.46
AURKA O14965 2/20 0.46
RPS6KB1 P23443 2/20 0.46
SYK P43405 1/20 0.44
ROCK1 Q13464 1/20 0.43
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
KAT6A Q92794 1/20 0.41
NTRK1 P04629 2/20 0.40
NTRK3 Q16288 1/20 0.40
NTRK2 Q16620 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633232 0.92 AURKA (0.46) METBRD4AURKARPS6KB1SYK
SCHEMBL13622970 0.88 SYK (0.51) METBRD4STK17BSTK17ASYK
SCHEMBL13623118 0.88 AURKA (0.50) METBRD4STK17BSTK17AAURKA
SCHEMBL4336930 0.86 LMNA (0.46) BRD4AURKARPS6KB1ROCK1NTRK1
SCHEMBL13623131 0.86 SYK (0.50) METBRD4STK17BSTK17AAURKA
SCHEMBL4180112 0.85 SYK (0.57) METBRD4STK17BSTK17ASYK
SCHEMBL13623129 0.85 SYK (0.47) METBRD4STK17BSTK17AAURKA
SCHEMBL12209794 0.84 AURKA (0.56) STK17BSTK17AAURKARPS6KB1JAK3
SCHEMBL13623023 0.84 MET (0.49) METBRD4STK17BSTK17AAURKA
SCHEMBL13623155 0.83 SYK (0.45) METBRD4STK17BSTK17AAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK MET 599/4885BRD4 342/4885STK17B 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.